Abeona Therapeutics Inc. (ABEO)
$
4.29
-0.04 (-0.93%)
Key metrics
Financial statements
Free cash flow per share
-1.5920
Market cap
244.7 Million
Price to sales ratio
42.0516
Debt to equity
0.1568
Current ratio
6.9295
Income quality
-1.0723
Average inventory
5.2 Million
ROE
0.5318
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases, reported depreciation and amortization expenses of $3,563,000.00 reflecting the wear and tear of its assets. The company demonstrated its financial health with an income before tax of $71,283,000.00 showcasing its pre-tax profitability. With a weighted average number of diluted shares outstanding of $66,135,821.00 the company highlights potential dilution effects that could arise. Operating expenses were also noted, as the company reported selling, general, and administrative expenses of $65,031,000.00 indicating its operational overhead costs. Furthermore, the weighted average number of shares outstanding is $52,952,917.00 which underscores the company’s shareholder base and their potential influence on its market strategies. Abeona's lead program, EB-101, is an autologous, gene-corrected cell therapy currently in Phase III clinical trials for recessive dystrophic epidermolysis bullosa, while the company is also advancing other therapeutic candidates targeting conditions such as Sanfilippo syndrome type A and cystic fibrosis. Within the financial landscape, the stock is affordable at $5.38 suitable for budget-conscious investors. However, it is noteworthy that the stock has a low average trading volume of $1,212,962.00 indicating lower market activity which may affect liquidity. With a market capitalization of $244,740,210.00 the company is classified as a small-cap player in the biopharmaceutical field. As a key player in the Biotechnology industry, Abeona contributes significantly to the overall market landscape, particularly through its innovative approaches to treating rare genetic disorders. Additionally, it belongs to the Healthcare sector, continuously driving innovation and growth within this vital area of healthcare. The ongoing development of its AAV-based gene therapy programs through the AIM vector platform exemplifies Abeona’s commitment to pioneering treatments, further enhancing its role in the evolving biopharmaceutical industry.
Is Abeona Therapeutics Inc. (ABEO) a good investment?
Investing in Abeona Therapeutics Inc. (ABEO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A, with a Bearish outlook. Always conduct your own research before investing.
What is Abeona Therapeutics Inc. (ABEO)'s stock forecast?
Analysts predict Abeona Therapeutics Inc. stock to fluctuate between $3.93 (low) and $7.54 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Abeona Therapeutics Inc.'s market capitalization?
As of 2026-03-30, Abeona Therapeutics Inc.'s market cap is $244,740,210, based on 57,049,000 outstanding shares.
How does Abeona Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Abeona Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Abeona Therapeutics Inc. pay dividends?
Abeona Therapeutics Inc. pays dividends. The current dividend yield is 8.55%, with a payout of $0.59 per share.
How can I buy Abeona Therapeutics Inc. (ABEO) stock?
To buy Abeona Therapeutics Inc. (ABEO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABEO. Place an order (Market, Limit, etc.).
What is the best time to invest in Abeona Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Abeona Therapeutics Inc. stock ever split?
Abeona Therapeutics Inc.'s last stock split was 1:25 on 2022-07-05.
How did Abeona Therapeutics Inc. perform in the last earnings report?
Revenue: $5,820,000 | EPS: $1.34 | Growth: -186.45%.
Where can I find Abeona Therapeutics Inc.'s investor relations reports?
Visit https://www.abeonatherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Abeona Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Abeona Therapeutics Inc. stock?
All-time high: $34 (2021-09-02) | All-time low: $2.19 (2023-02-24).
What are the key trends affecting Abeona Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Abeona Therapeutics maintains a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. ZEVASKYN is the first autologous cell sheet-based gene therapy for RDEB, with FDA approval and broad payer access, targeting a >$4B cumulative revenue opportunity. Profitability is achievable by treating just three RDEB patients per month; demand doubled from 50 to 100 eligible patients, with seven QTCs expected by year-end 2026.
seekingalpha.com
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
globenewswire.com
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 - CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2025 and recent operational progress. “2026 is about building a steady cadence of biopsies and treatments,” said Vish Seshadri, Chief Executive Officer of Abeona.
globenewswire.com
CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company's launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
defenseworld.net
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have been given an average rating of "Moderate Buy" by the five analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average
globenewswire.com
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy and business development functions, as well as drive operating efficiency for the Company.
globenewswire.com
CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN, a first-of-its-kind, FDA-approved autologous, gene therapy is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
globenewswire.com
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN was administered at Lucile Packard Children's Hospital Stanford in Palo Alto, CA.
seekingalpha.com
Abeona Therapeutics delivered strong 3Q25 results, with a narrowed net loss and $207.5 million in cash supporting a two-year runway. Zevaskyn's commercial launch is delayed to 4Q25 due to FDA assay requirements, but demand and payer coverage remain robust, aided by a new CMS J-code. ABEO's financials improved significantly, with reduced R&D expenses and a strengthened balance sheet, positioning the company well for commercialization.
seekingalpha.com
Abeona Therapeutics Inc. ( ABEO ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Gregory Gin - Vice President of Investor Relations & Corporate Communications Vishwas Seshadri - President, CEO & Director Brian Kevany - Senior VP, CTO & CSO Madhav Vasanthavada - Senior VP, Chief Commercial Officer & Head of Business Development Joseph Vazzano - Chief Financial Officer Conference Call Participants Mohamad Amin Makarem - Jefferies LLC, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division David Bautz - Zacks Small-Cap Research Presentation Operator Good morning, everyone, and welcome to the Abeona Therapeutics Third Quarter 2025 Conference Call.
See all news
